^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    HDAC2 (Histone deacetylase 2)

    i
    Other names: HDAC2, RPD3, YAF1, Histone deacetylase 2
    3d
    HDAC3 inhibition as a therapeutic strategy in T-cell acute lymphoblastic leukemia via the TYK2-STAT1-BCL2 signaling pathway. (PubMed, Front Immunol)
    HDAC3 was found to associate with TYK2 and contributed to activation of the TYK2-STAT1-BCL2 signaling pathway in T-ALL cells. Our results highlight the effectiveness of the combination of chidamide and chemotherapy in the treatment of T-ALL patients and suggest that HDAC3 can act as a potential novel therapeutic target to inhibit the TYK2-STAT1-BCL2 signaling pathway in T-ALL.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • HDAC2 (Histone deacetylase 2) • TYK2 (Tyrosine Kinase 2) • HDAC10 (Histone Deacetylase 10) • HDAC3 (Histone Deacetylase 3)
    |
    Epidaza (chidamide)
    6d
    Elucidating key targets and mechanisms of diethyl phthalate-induced colorectal cancer through network toxicology and molecular docking. (PubMed, PLoS One)
    This study provides a theoretical framework for exploring the molecular mechanisms through which DEP may contribute to CRC development, emphasizing the value of network toxicology in cancer research. These findings may inform future investigations into the risks of DEP exposure and support public health policy and the development of targeted therapeutic strategies.
    Journal
    |
    EP300 (E1A binding protein p300) • HDAC2 (Histone deacetylase 2) • TGFB1 (Transforming Growth Factor Beta 1) • HDAC1 (Histone Deacetylase 1)
    14d
    Downregulation of ClC-3 chloride channels in dorsal root ganglia neurons contributes to bone metastasis-induced pain. (PubMed, J Biol Chem)
    Activation of the IGF1/IGF1R-AKT signaling pathway promotes HDAC2-mediated epigenetic silencing of Clc-3, thereby enhancing neuronal excitability and pain hypersensitivity in tumor-bearing rats. Our findings reveal a new and targetable mechanism underlying bone metastasis-induced pain, offering promising therapeutic avenues for pain management in cancer patients.
    Journal
    |
    IGF1 (Insulin-like growth factor 1) • HDAC2 (Histone deacetylase 2)
    19d
    Delactylation of the tumor suppressor ARHGDIB drives metastasis and chemoresistance in bladder cancer. (PubMed, Cell Rep)
    Entinostat, an inhibitor of class I HDAC, synergizes with cisplatin by preventing ARHGDIB delactylation. Collectively, our findings unveil a unique paradigm in which delactylation of tumor suppressors drives metastasis and chemoresistance. Targeting lactylation dynamics with HDAC inhibitors presents an avenue for intervention of bladder cancer.
    Journal
    |
    CHEK2 (Checkpoint kinase 2) • RAC1 (Rac Family Small GTPase 1) • HDAC2 (Histone deacetylase 2) • ARHGDIB (Rho GDP Dissociation Inhibitor Beta)
    |
    cisplatin • Jingzhuda (entinostat)
    25d
    Discovery of Tertiary Benzenesulfonanilide Chemotypes as HDAC Inhibitors via Multistrategy In Silico and Biological Evaluation for Colon Cancer Therapy. (PubMed, J Med Chem)
    Mechanistically, HIT211504993 inhibits Myc-driven tumorigenesis by promoting nucleocytoplasmic acetylation and modulating p53, cell-cycle, and Wnt/β-catenin signaling. The investigation of antitumor activity and its mechanism of action provides a theoretical basis for the development of the next-generation benzenesulfonanilide HDAC inhibitors.
    Journal
    |
    HDAC2 (Histone deacetylase 2) • HDAC4 (Histone Deacetylase 4)
    |
    Zolinza (vorinostat)
    1m
    Reversing enhancer RNA-mediated IKBKE gene repression enables synthetic anticancer immunity in prostate cancer models. (PubMed, J Clin Invest)
    IKBKE-e ablation largely enhanced innate immunity in prostate cancer cells in culture and anticancer immunity in mice. Our results revealed AR, HDAC2, and IKBKE eRNA as critical intrinsic immune suppressors in prostate cancer cells, suggesting that rejuvenating inhibitor of nuclear factor kappa-B kinase subunit epsilon (IKKε) signaling by targeting IKBKE-e is an actionable strategy to elicit synthetic anticancer immunity in immunologically "cold" cancers such as prostate cancer.
    Preclinical • Journal
    |
    HDAC2 (Histone deacetylase 2) • IFIH1 (Interferon Induced With Helicase C Domain 1) • IKBKE (Inhibitor Of Nuclear Factor Kappa B Kinase Subunit Epsilon)
    2ms
    Targeting Class I Histone Deacetylases Triggers Antitumor Responses in Colorectal Cancer In Vitro and In Vivo. (PubMed, J Med Chem)
    The short-term in vitro effects of 5d were modulated by a compensatory upregulation of autophagy. However, in long-term, this protective mechanism becomes insufficient to sustain tumor survival, resulting in strong antitumor efficacy in vivo in the CAM assay for both compounds even outperforming entinostat.
    Preclinical • Journal
    |
    HDAC2 (Histone deacetylase 2) • HDAC1 (Histone Deacetylase 1) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • HDAC3 (Histone Deacetylase 3)
    |
    Jingzhuda (entinostat)
    2ms
    Brahmi (Bacopa monnieri) plant preparation facilitates to enhance the activities of dendritic cells to control non-small cell lung cancer (NSCLC). (PubMed, J Cancer Res Clin Oncol)
    Overall, these findings demonstrate the ability of BPP to influence dendritic and T-cell responses in NSCLC via coordinated transcriptional and chromatinremodelling activities.
    Journal
    |
    TP53 (Tumor protein P53) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • STAT3 (Signal Transducer And Activator Of Transcription 3) • IL10 (Interleukin 10) • HDAC2 (Histone deacetylase 2) • TBX21 (T-Box Transcription Factor 21) • FOXP3 (Forkhead Box P3) • IL17A (Interleukin 17A) • STAT1 (Signal Transducer And Activator Of Transcription 1) • STAT6 (Signal transducer and activator of transcription 6) • IL4 (Interleukin 4) • STAT2 (Signal transducer and activator of transcription 2) • STAT5A (Signal Transducer And Activator Of Transcription 5A) • CD1D (CD1d Molecule) • CD80 (CD80 Molecule) • CD86 (CD86 Molecule) • STAT4 (Signal Transducer And Activator Of Transcription 4)
    2ms
    Ortho-Hydroxyanilides: Slow-Acting, Selective Histone Deacetylase 1/2 Inhibitors Suitable for Photocaging Applications. (PubMed, ACS Pharmacol Transl Sci)
    To this end, we compared the ortho-hydroxyanilide derivative ST13 with the pan-HDAC inhibitor vorinostat and Cpd-60, an ortho-aminoanilide with high HDAC1/HDAC2 selectivity...Furthermore, we demonstrated that the light-activatable prodrug ST17 readily releases ST13 upon irradiation, thereby allowing to precisely control its antiproliferative properties. These findings validate ortho-hydroxyanilides as effective HDAC1/HDAC2-selective inhibitors and highlight photocaging as a promising strategy to achieve spatiotemporal control of epigenetic therapies in cancer.
    Journal
    |
    HDAC2 (Histone deacetylase 2) • HDAC1 (Histone Deacetylase 1)
    |
    Zolinza (vorinostat)
    2ms
    Disclosure of Potential Therapeutic Targets in Plumbagin for Treating Osteosarcoma. (PubMed, Biomed Eng Comput Biol)
    Our preclinical study investigates the possible therapeutic mechanism of plumbagin against osteosarcoma, indicating that plumbagin exhibited anti-osteosarcoma features via regulation of core target genes associated with autophagy. Current research findings may provide the scientific ideas and evidences for screening bioactive compound against osteosarcoma.
    Journal
    |
    PARP1 (Poly(ADP-Ribose) Polymerase 1) • HDAC2 (Histone deacetylase 2)
    2ms
    Nuclear PD-L1 drives IFN-γ-promoted lung metastasis of triple-negative breast cancer via POLR2A-mediated transcriptional activation of LY6E. (PubMed, Breast Cancer Res)
    Our findings unveil a novel IFN-γ-nuclear PD-L1/POLR2A-LY6E signaling axis critical for TNBC lung metastasis. This immune-independent mechanism, driven by nuclear PD-L1 transcriptional activity, provides a mechanistic basis for the limited efficacy of anti-PD-L1 antibodies against metastasis and nominates nuclear PD-L1 complexes and LY6E as potential therapeutic targets to overcome metastatic resistance in TNBC.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • IFNG (Interferon, gamma) • HDAC2 (Histone deacetylase 2) • LY6E (Lymphocyte Antigen 6 Family Member E)
    |
    PD-L1 expression • PD-L1 overexpression